Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886271 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL5886496 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2AGAAMEN1 | |
| SCHEMBL5886260 | 0.83 | KMT2A (0.51) | ALDH1A1KDM4EKMT2AGAAATM | |
| SCHEMBL30149921 | 0.83 | KMT2A (0.67) | ALDH1A1KDM4EKMT2AGAAATM | |
| SCHEMBL3725674 | 0.83 | KMT2A (0.67) | ALDH1A1KDM4EKMT2AGAAATM | |
| SCHEMBL5886249 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAMAPTLMNA | |
| SCHEMBL5886447 | 0.81 | KMT2A (0.54) | ALDH1A1KDM4EKMT2AGAAATM | |
| SCHEMBL5886270 | 0.81 | GAA (0.52) | ALDH1A1KDM4EKMT2AGAAATM | |
| SCHEMBL5886240 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KDM4EKMT2AGAAMEN1 | |
| SCHEMBL5886245 | 0.81 | KDM4E (0.41) | ALDH1A1KDM4EKMT2AGAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | ALDH1A1 3766/4885KDM4E 3704/4885KMT2A 3473/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | ALDH1A1 2334/4885KDM4E 1785/4885KMT2A 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.